STREngthening COronavirus Disease 2019 (COVID-19) Surveillance in Africa
Conditions: COVID-19; SARS CoV 2 Infection; COVID-19 Pandemic Sponsors: Institut de Recherche pour le Developpement; European and Developing Countries Clinical Trials Partnership (EDCTP); Institut de Recherche Clinique du B énin; Barcelona Institute for Global Health; Ministère de la Santé - Bénin; Ministère de la Santé et de Hygiène Publique - Burkina Faso Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 14, 2023 Category: Research Source Type: clinical trials
STREngthening COVID-19 Surveillance in Africa
Conditions: COVID-19; SARS CoV 2 Infection; COVID-19 Pandemic Sponsors: Institut de Recherche pour le Developpement; European and Developing Countries Clinical Trials Partnership (EDCTP); Institut de Recherche Clinique du B énin; Barcelona Institute for Global Health; Ministère de la Santé - Bénin; Ministère de la Santé et de Hygiène Publique - Burkina Faso Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 14, 2023 Category: Research Source Type: clinical trials
Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India
Conditions: Influenza; COVID-19; SARS-COV-2 Infection; Other Respiratory Viruses; Perinatal Morbidity; Infant Morbidity Interventions: Other: Exposures Sponsors: Boston University; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Lata Medical Research Foundation, Nagpur Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 13, 2023 Category: Research Source Type: clinical trials
A Phase 1 Trial of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination
Conditions: SARS-CoV-2; COVID-19 Vaccine Interventions: Biological: 30 μg dose of LYB002V14; Biological: 60μg dose of LYB002V14; Biological: placebo Sponsors: Guangzhou Patronus Biotech Co., Ltd.; Yantai Patronus Biotech Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 13, 2023 Category: Research Source Type: clinical trials
Severe Acute Respiratory Syndrome Coronavirus 2 Re-Infection Risk and Vaccine Efficacy in Austria
Conditions: COVID-19 Interventions: Biological: Vaccination against SARS-CoV-2 Sponsors: Medical University of Graz; AGES; Medical University Innsbruck; Austrian Science Fund (FWF) Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
Reducing sick leave, improving work ability, and quality of life in patients with mild to moderate Long COVID through psychosocial, physiotherapeutic, and nutritive supportive digital intervention (MiLoCoDaS): study protocol for a randomized controlled trial
DiscussionIf one of the two interventions is superior to providing information alone, MiLoCoDaS would provide the starting point for a rapidly scalable digital intervention for the frequent and currently underserved patient group with mild to moderate impairment from Long COVID. Several caveats pertain to the heterogeneity of Long COVID manifestation and duration prior to inclusion. It is conceivable that the possible effect of the intervention may differ across subgroups. Therefore, a priori defined secondary analysis will be conducted.Trial registrationGerman Clinical Trials Register (DRKS) DRKS00028964. Registered on 24...
Source: Trials - December 8, 2023 Category: Research Source Type: clinical trials
COVID-19 Pharmacotherapy Effectiveness in the VA Healthcare System
Conditions: COVID-19, SARS-CoV-2 Infection; COVID-19, SARS-CoV-2 Infection, RSV, Influenza Sponsors: VA Office of Research and Development; Department of Health and Human Services; Food and Drug Administration (FDA) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials
A Randomized Trial Evaluating a mRNA VLP Vaccine's Immunogenicity and Safety for COVID-19
Conditions: COVID-19; SARS-CoV-2 Infection Interventions: Biological: AZD9838; Biological: Licensed mRNA vaccine Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 27, 2023 Category: Research Source Type: clinical trials
Collection of Additional Biological Samples From Potentially COVID-19 Patients for Monitoring of Biological Parameters Carried Out as Part of the Routine
Conditions: SARS CoV 2 Infection Interventions: Diagnostic Test: RIPH2 Sponsors: CerbaXpert Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 22, 2023 Category: Research Source Type: clinical trials
Development and Qualification of Methods for Analyzing the Mucosal Immune Response to COVID-19
Conditions: Certain Disorders Involving the Immune Mechanism Interventions: Biological: Sampling; Biological: PCR (polymerase chain reaction) SARS-CoV-2 Sponsors: University Hospital, Tours Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 21, 2023 Category: Research Source Type: clinical trials
Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age
Conditions: SARS-CoV-2 Infection; COVID-19 Interventions: Biological: BNT162b2; Other: Placebo; Biological: Seasonal Inactivated Influenza Vaccine Sponsors: Pfizer Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials
Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
Conditions: SARS-CoV-2 Interventions: Biological: SPIKEVAX Sponsors: ModernaTX, Inc.; Aetion, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 14, 2023 Category: Research Source Type: clinical trials
Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years
Conditions: SARS-CoV-2; COVID-19 Interventions: Biological: COMIRNATY intramuscular injection Sponsors: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 14, 2023 Category: Research Source Type: clinical trials
The Safety and Tolerability of A8G6 COVID-19 Neutralization Antibody Combined With Nasal Spray
Conditions: SARS-CoV-2; Prevention Interventions: Biological: A8G6 SARS-CoV-2 Neutralization Antibody combination nasal spray; Other: A8G6 SARS-CoV-2 Neutralization Antibody nasal excipient Sponsors: The Second Affiliated Hospital of Chongqing Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2023 Category: Research Source Type: clinical trials
A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine
Conditions: SARS-CoV-2 Infection Interventions: Biological: Placebo; Biological: COVID-19 Vaccine (Vero Cell) ,Inactivated; Biological: COVID-19 mRNA Vaccine (ZSVG-02-O) 10 μg; Biological: COVID-19 mRNA Vaccine (ZSVG-02-O) 30 μg; Biological: COVID-19 mRNA Vaccine (ZSVG-02-O) 60 μg Sponsors: CNBG-Virogin Biotech (Shanghai) Ltd.; Shulan (Hangzhou) Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials
